BlackRock, Inc. acquired a security interest in 3.90 million shares of InnoCare Pharma Ltd. on October 27, 2026; this was an off-exchange transaction and the consideration was non-cash assets. It was not matched on the SEHK open market and therefore not a direct secondary-market dealing.
Prior to the acquisition, BlackRock, Inc.’s long position in InnoCare Pharma Ltd. was 72.62 million shares, representing 4.85%; following the acquisition, the holding changed to 76.52 million shares, with the long position ratio rising to 5.11%.